Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Real-world treatment patterns for HER2-amplified colorectal cancer

John Strickler • 21 Oct 2023
ESMO 2023
Colorectal Cancer Gastrointestinal Cancer Antibodies Trastuzumab Tucatinib

John Strickler, MD, Duke Cancer Institute, Durham, NC, comments on the how HER2-amplified colorectal cancer (CRC) is treated in real-world settings. Despite anti-HER2 therapies such as tucatinib and trastuzumab in current treatment guidelines, only approximately half of patients with HER2-amplified CRC are receiving the recommended treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from John Strickler

0:44
Using ctDNA to identify mutations in colorectal cancer
John Strickler • 21 Oct 2023
0:58
MOUNTAINEER: clinical relevance of genomic profiling for tucatinib + trastuzumab treatment in mCRC
John Strickler • 21 Oct 2023
2:28
MOUNTAINEER: impact of genomic alterations on tucatinib plus trastuzumab activity in mCRC
John Strickler • 21 Oct 2023
0:55
Key themes in colorectal cancer at ESMO WCGIC 2023
John Strickler • 29 Jun 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals